Outcomes of First-Line Anti-PD-L1 Blockades Combined with Brain Radiotherapy (BRT) for Extensive-Stage SmallCell Lung Cancer (ES-SCLC) with Brain Metastases (BM)

被引：0
|
作者：
Tian, Y. [1 ]
Ma, J. [2 ]
Zhu, H. [3 ]
Yu, J. [3 ]
机构：
[1] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2804
引用
收藏
页码：E360 / E360
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
    Chen, Dawei
    Zou, Bing
    Meng, Xiangjiao
    Huang, Wei
    Shao, Qian
    Tang, Xiaoyong
    Guo, Jun
    Hu, Xudong
    Zhang, Yan
    Fu, Lei
    Yuan Jiajia
    Yu, Jinming
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Radioactive Seed Implantation Combined with PD-L1 Antibody and Chemotherapy Gt in the First-Line Treatment of ES-SCLC: A Retrospective Study
    Li, X.
    Zhang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S669 - S669
  • [43] First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
    Lijuan Li
    Dan Yang
    Yanmei Min
    Anyan Liao
    Jing Zhao
    Leilei Jiang
    Xin Dong
    Wei Deng
    Huiming Yu
    Rong Yu
    Jun Zhao
    Anhui Shi
    BMC Cancer, 23
  • [44] IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
    Califano, R.
    Kazarnowicz, A.
    Karaseva, N.
    Sanchez, A.
    Liu, S. V.
    Horn, L.
    Quach, C.
    Yu, W.
    Kabbinavar, F.
    Lam, S.
    Mansfield, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 17 - 17
  • [45] Efficacy of First-Line Immunotherapy Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients With Different Brain Metastases Status: A Systematic Review and Meta-Analysis
    Zhao, Wen Hua
    Wang, Shou Feng
    Su, Cui Yun
    Pan, Xin Bin
    WORLD JOURNAL OF ONCOLOGY, 2023, 14 (06) : 529 - 539
  • [46] Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study
    Yu, Yongfeng
    Yu, Yan
    Zhang, Yan
    Zhang, Wei
    Lv, Dongqing
    Chen, Yuan
    Huang, Dingzhi
    Zhang, Mingjun
    Li, Yongsheng
    Li, Dairong
    Gao, Junzhen
    Wu, Lin
    He, Zhiyong
    Shi, Jianhua
    Zhao, Mingfang
    Liu, Anwen
    Wang, Chunyue
    Zhu, Hui
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)
    Lai, W. C. V.
    Ahn, M-J.
    Shentzer, T.
    Kowalski, D.
    Cho, B. C.
    Schmid, S.
    Jove, M.
    Huang, M.
    Zhao, B.
    El-Osta, H.
    Navarro, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1425 - S1426
  • [48] A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
    Chu, Q.
    Parikh, K.
    Paz-Ares, L.
    Navarro, A.
    Markman, B.
    Sarmiento, R.
    Kollia, G.
    He, C.
    Sanghavi, K.
    Chang, H.
    Fischer, B.
    Guha, U.
    Tannenbaum-Dvir, S.
    Wu, K.
    Liu, Y.
    Ready, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1170 - S1170
  • [49] First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
    Li, Lijuan
    Yang, Dan
    Min, Yanmei
    Liao, Anyan
    Zhao, Jing
    Jiang, Leilei
    Dong, Xin
    Deng, Wei
    Yu, Huiming
    Yu, Rong
    Zhao, Jun
    Shi, Anhui
    BMC CANCER, 2023, 23 (01)
  • [50] Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)
    Rodriguez-Abreu, Delvys
    Hochmair, Maximillian
    Cho, Byoung Chul
    Csoszi, Tibor
    Kutiel, Talia Shentzer
    Mueller, Veronika
    Ahn, Myung-Ju
    Kowalski, Dariusz
    Maio, Michele
    Moiseyenko, Vladimir
    Navarro, Alejandro
    Niu, Jianxin
    Fung, Andrea S.
    Lips, Carolin
    Zhou, Heng
    Zhao, Bin
    Lara-Guerra, Humberto
    Peled, Nir
    CANCER RESEARCH, 2024, 84 (07)
12345